Clinical Trial Detail

NCT ID NCT02970981
Title Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Age Groups: adult child senior

No variant requirements are available.